Gilead Sciences (NASDAQ:GILD) was downgraded by equities researchers at TheStreet from a “b-” rating to a “c” rating in a note issued to investors on Tuesday.

Other equities analysts have also issued reports about the company. William Blair restated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Mizuho upped their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $73.67 to $94.00 in a research note on Thursday, November 30th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average price target of $86.89.

Shares of Gilead Sciences (NASDAQ GILD) traded down $1.01 during midday trading on Tuesday, reaching $81.75. The company’s stock had a trading volume of 3,669,475 shares, compared to its average volume of 9,667,725. The company has a market cap of $107,090.00, a price-to-earnings ratio of 23.70, a P/E/G ratio of -1.77 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 48.88% and a net margin of 17.73%. The company’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.70 EPS. sell-side analysts expect that Gilead Sciences will post 6.47 EPS for the current fiscal year.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the sale, the chairman now owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 578,333 shares of company stock valued at $44,100,508. Company insiders own 1.30% of the company’s stock.

Large investors have recently made changes to their positions in the company. Welch Investments LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $144,000. Hanson & Doremus Investment Management raised its position in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $147,000. 75.84% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences (GILD) Rating Lowered to C at TheStreet” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2018/02/08/gilead-sciences-gild-rating-lowered-to-c-at-thestreet.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.